Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

REFERENCES

1. 1.↵
   1. Cohen SB,
   2. Emery P,
   3. Greenwald MW,
   4. Dougados M,
   5. Furie RA,
   6. Genovese MC,
   7. et al;
   8. REFLEX Trial Group

   . Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Keystone E,
   2. Emery P,
   3. Peterfy CG,
   4. Tak PP,
   5. Cohen S,
   6. Genovese MC,
   7. et al.

   Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216–21.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. van Vollenhoven RF,
   2. Emery P,
   3. Bingham CO 3rd,
   4. Keystone EC,
   5. Fleischmann RM,
   6. Furst DE,
   7. et al.

   Longterm safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496–502.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Loveless J,
   2. Olech E,
   3. Pritchard CH,
   4. Chai A,
   5. Kelman A,
   6. Klearman M

   . An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL). Arthritis Rheum 2009;60 Suppl 10:1660.

   OpenUrl
5. 5.↵
   1. Emery P,
   2. Fleischmann R,
   3. Filipowicz-Sosnowska A,
   4. Schechtman J,
   5. Szczepanski L,
   6. Kavanaugh A,
   7. et al;
   8. DANCER Study Group

   . The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390–400.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Keystone E,
   2. Fleischmann R,
   3. Emery P,
   4. Furst DE,
   5. van Vollenhoven R,
   6. Bathon J,
   7. et al.

   Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896–908.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Emery P,
   2. Deodhar A,
   3. Rigby WF,
   4. Isaacs JD,
   5. Combe B,
   6. Racewicz AJ,
   7. et al.

   Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629–35.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Tak PP,
   2. Rigby WF,
   3. Rubbert-Roth A,
   4. Peterfy CG,
   5. van Vollenhoven RF,
   6. Stohl W,
   7. et al;
   8. IMAGE Investigators

   . Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39–46.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   Centers for Disease Control and Prevention. National Vital Statistics Reports. Deaths: final data for 2005. [Internet. Accessed June 30, 2015.] Available from: www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56_10.pdf
10. 10.↵
    1. Dixon WG,
    2. Watson KD,
    3. Lunt M,
    4. Hyrich KL;
    5. British Society for Rheumatology Biologics Register Control Centre Consortium,
    6. Silman AJ,
    7. et al.

    Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905–12.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Mellemkjaer L,
    2. Linet MS,
    3. Gridley G,
    4. Frisch M,
    5. Møller H,
    6. Olsen JH

    . Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753–7.

    OpenUrlCrossRef
12. 12.↵
    1. Wolfe F,
    2. Michaud K

    . Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886–95.

    OpenUrlCrossRefPubMed
13. 13.↵
    National Cancer Institute. Surveillance, epidemiology, and end results. [Internet. Accessed June 30, 2015.] Available from: seer.cancer.gov
14. 14.↵
    1. Smitten AL,
    2. Simon TA,
    3. Hochberg MC,
    4. Suissa S

    . A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Fleischmann RM

    . Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225–8.

    OpenUrlCrossRefPubMed